# Entrada Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/entrada-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 21 | | Claims under review | 1 | | Evidence records | 4 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-26T14:47:07.555553+00:00 | | Last reviewed | 2026-10-26T14:47:07.555553+00:00 | ## Identity - Legal name: Entrada Therapeutics, Inc. - Display name: Entrada Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-27T01:31:45.426352+00:00 | | Completeness | 0.364 | | Record Quality | 0.833 | | Directors | 12 | | Committees | 0 | | Governance events | 9 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | NOT_REVIEWED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Bernhardt Zeiher: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2023-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:6 - Dipal Doshi: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2017-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:8 - Gina Chapman: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2023-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:9 - Kush M. Parmar: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2016-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:10 - Maha Radhakrishnan: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2025-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:11 - Mary Thistle: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2021-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:13 - Natarajan Sethuraman: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2017-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:14 - Peter S. Kim: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:15 - Bernhardt Zeiher, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:7 - Kush M. Parmar, M.D., Ph.D.: Board Chairman. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:5 - Maha Radhakrishnan, M.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:12 - Peter S. Kim, Ph.D.: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:16 ## Executive leadership - Natarajan Sethuraman: President of Research and Development [PRESIDENT]. Status: current. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:19 - Dipal Doshi: Chief Executive Officer [CEO]. Status: unknown. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:17 - Kory Wentworth: Chief Financial Officer [CFO]. Status: unknown. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:18 - Natarajan Sethuraman, Ph.D.: President of Research and Development [PRESIDENT]. Status: unknown. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:20 - Nathan J. Dowden: President and Chief Operating Officer [COO]. Status: unknown. claim_id=alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:21 ## Governance events - EXECUTIVE_APPOINTED: Natarajan Sethuraman executive of Entrada Therapeutics, Inc., effective 2026-04-24. Effective: 2026-04-24. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:1y6cagchbm9u - DIRECTOR_APPOINTED: Maha Radhakrishnan seat on Entrada Therapeutics, Inc., effective 2025-01-01. Effective: 2025-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:djrotz13ujeiv - DIRECTOR_APPOINTED: Bernhardt Zeiher seat on Entrada Therapeutics, Inc., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:1imlwwj15cbmjz - DIRECTOR_APPOINTED: Gina Chapman seat on Entrada Therapeutics, Inc., effective 2023-01-01. Effective: 2023-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:70dlnaa9sqms - DIRECTOR_APPOINTED: Mary Thistle seat on Entrada Therapeutics, Inc., effective 2021-01-01. Effective: 2021-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:1aezxm1eiv7zt - DIRECTOR_APPOINTED: Peter S. Kim seat on Entrada Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:ujtkeii7lvku - DIRECTOR_APPOINTED: Dipal Doshi seat on Entrada Therapeutics, Inc., effective 2017-01-01. Effective: 2017-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:errym4cj99hu - DIRECTOR_APPOINTED: Natarajan Sethuraman seat on Entrada Therapeutics, Inc., effective 2017-01-01. Effective: 2017-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:1xmw32numly2j - DIRECTOR_APPOINTED: Kush M. Parmar seat on Entrada Therapeutics, Inc., effective 2016-01-01. Effective: 2016-01-01. Detected: 2026-10-26T14:47:07.555553+00:00. event_id=alpha:event:transition:51izeqgfob4e ## Scoped resources - `alpha://company/entrada-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record - `alpha://company/entrada-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=identity - `alpha://company/entrada-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/entrada-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=board - `alpha://company/entrada-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=committees - `alpha://company/entrada-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=leadership - `alpha://company/entrada-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=ownership - `alpha://company/entrada-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=financials - `alpha://company/entrada-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/entrada-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=compensation - `alpha://company/entrada-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=governance - `alpha://company/entrada-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/entrada-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=audit - `alpha://company/entrada-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=legal - `alpha://company/entrada-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=risk - `alpha://company/entrada-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=cyber - `alpha://company/entrada-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/entrada-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=agents - `alpha://company/entrada-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/entrada-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=events - `alpha://company/entrada-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=relationships - `alpha://company/entrada-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=assessments - `alpha://company/entrada-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - Kush M. Parmar, M.D., Ph.D.: Board Chairman. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Bernhardt Zeiher: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:6. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Bernhardt Zeiher, M.D.: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Dipal Doshi: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:8. Valid from: 2017-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Gina Chapman: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:9. Valid from: 2023-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Kush M. Parmar: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:10. Valid from: 2016-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Maha Radhakrishnan: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:11. Valid from: 2025-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Maha Radhakrishnan, M.D.: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:12. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Mary Thistle: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:13. Valid from: 2021-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Natarajan Sethuraman: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:14. Valid from: 2017-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Peter S. Kim: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:15. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10. - Peter S. Kim, Ph.D.: Director. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:16. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Dipal Doshi: Chief Executive Officer. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Kory Wentworth: Chief Financial Officer. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Natarajan Sethuraman: President of Research and Development. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:19. Valid from: 2026-04-24. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:dfdf49a67ffc219bcd56e6e351c41ff51388519e3c46af95ee69ce7dda55649e. - Natarajan Sethuraman, Ph.D.: President of Research and Development. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. - Nathan J. Dowden: President and Chief Operating Officer. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:leadership_role:21. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - Entrada Therapeutics, Inc.. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:d914e5c46b2bfd5958878df0b3fc8ff2dae148c214a78e51b5156fb302ef0c2c. ## Entity Status - Public listing published. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:d914e5c46b2bfd5958878df0b3fc8ff2dae148c214a78e51b5156fb302ef0c2c. ## Published Fact - US. Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:d914e5c46b2bfd5958878df0b3fc8ff2dae148c214a78e51b5156fb302ef0c2c. ## Security Listing - TRDA (NASDAQ). Claim: alpha:claim:company:994f0aa1-40ac-431e-a75c-0aa8be4df41a:security_listing:22. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:d914e5c46b2bfd5958878df0b3fc8ff2dae148c214a78e51b5156fb302ef0c2c. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:d914e5c46b2bfd5958878df0b3fc8ff2dae148c214a78e51b5156fb302ef0c2c: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/entrada-therapeutics-inc). - alpha:projection-evidence:document:648d8db272463e3265e31a0092b8f82d01c8d4ad1abf173486010126ecdec3c2: [SEC DEF 14A 0001689375-26-000021](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000021/trda-20260424.htm). - alpha:projection-evidence:document:6a34c49d1d9ce39d75239c37c4ae945dc8899135b3ff1d50c209dcf7c1683c10: [DEF 14A trda-20260424.htm](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000021/trda-20260424.htm). - alpha:projection-evidence:document:dfdf49a67ffc219bcd56e6e351c41ff51388519e3c46af95ee69ce7dda55649e: [TRDA DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1689375/000168937526000021/trda-20260424.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/entrada-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/entrada-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/entrada-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/entrada-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-27T01:31:45.11188+00:00; recorded 2026-10-27T01:31:45.11188+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.